Skip to content
Politically.com Search all
Menu

2026 · 3rd Quarter (July 1 - Sep 30)

BIOTECHNOLOGY INNOVATION ORGANIZATION

Filed by DLA PIPER LLP (US).

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-11-01 06:26:09 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 19, 2026
Income
$60,000.00
Expenses
Not reported
Filing UUID
78894e23-7b43-4d8b-a00f-cd517450124e
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

340B drug discount program. General issues related to health care. Issues related to FDA drug review, including PDUFA.

MED · Medical/Disease Research/Clinical Labs

Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.

HCR · Health Issues

Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.

MMM · Medicare/Medicaid

Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues. IRA implementation.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.